Vistagen Therapeutics Inc (NASDAQ:VTGN) Expected to Announce Earnings of -$0.07 Per Share

Share on StockTwits

Analysts expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to announce ($0.07) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics posted earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The company is scheduled to report its next earnings report on Tuesday, February 11th.

On average, analysts expect that Vistagen Therapeutics will report full year earnings of ($0.40) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.35) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Vistagen Therapeutics.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01.

A number of analysts recently issued reports on the company. Maxim Group set a $4.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 15th. Chardan Capital reissued a “hold” rating and set a $0.70 price objective on shares of Vistagen Therapeutics in a report on Sunday, November 3rd. Finally, William Blair cut Vistagen Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $2.35.

VTGN traded up $0.02 during trading on Wednesday, reaching $0.44. 364,999 shares of the company were exchanged, compared to its average volume of 361,136. The company’s 50-day moving average is $0.85 and its two-hundred day moving average is $0.80. The company has a market cap of $20.75 million, a price-to-earnings ratio of -0.49 and a beta of -0.57. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 2.44. Vistagen Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.86.

A number of institutional investors and hedge funds have recently modified their holdings of VTGN. Wells Fargo & Company MN purchased a new stake in Vistagen Therapeutics during the 2nd quarter worth about $31,000. LPL Financial LLC bought a new position in Vistagen Therapeutics in the 2nd quarter worth about $27,000. HighTower Advisors LLC increased its stake in Vistagen Therapeutics by 326.3% in the 2nd quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after acquiring an additional 101,308 shares during the last quarter. Vanguard Group Inc. increased its stake in Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after acquiring an additional 35,729 shares during the last quarter. Finally, D.A. Davidson & CO. increased its stake in Vistagen Therapeutics by 27.3% in the 3rd quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after acquiring an additional 22,500 shares during the last quarter. 8.61% of the stock is currently owned by institutional investors and hedge funds.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nomura Holdings Inc. Lowers Stock Holdings in Vornado Realty Trust
Nomura Holdings Inc. Lowers Stock Holdings in Vornado Realty Trust
Nomura Holdings Inc. Trims Stock Holdings in RingCentral Inc
Nomura Holdings Inc. Trims Stock Holdings in RingCentral Inc
Nomura Holdings Inc. Purchases 30,062 Shares of ANI Pharmaceuticals Inc
Nomura Holdings Inc. Purchases 30,062 Shares of ANI Pharmaceuticals Inc
Nomura Holdings Inc. Has $23.57 Million Stock Holdings in Booz Allen Hamilton Holding Co.
Nomura Holdings Inc. Has $23.57 Million Stock Holdings in Booz Allen Hamilton Holding Co.
Instructure Inc  Holdings Lifted by Nomura Holdings Inc.
Instructure Inc Holdings Lifted by Nomura Holdings Inc.
Nomura Holdings Inc. Acquires 18,909 Shares of Cooper Companies Inc
Nomura Holdings Inc. Acquires 18,909 Shares of Cooper Companies Inc


 
© 2006-2019 Zolmax.